CardiAMP is under clinical development by BioCardia and currently in Phase III for Systolic Heart Failure. According to GlobalData, Phase III drugs for Systolic Heart Failure have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how CardiAMP’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BioCardia is a regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The company develops biotherapeutic candidates that include a CardiAMP cell therapy system, autologous minimally processed bone marrow cells and an allogeneic off-the-shelf mesenchymal stem a cell product candidate for ischemic systolic heart failure. BioCardia‘s CardiAMP cell therapy system comprises a cell potency screening test, a point-of-care cell processing platform, and a biotherapeutic delivery system. The company sells its products through a network of distributors across the US. BioCardia is headquartered in San Carlos, California, the US
For a complete picture of CardiAMP’s drug-specific PTSR and LoA scores, buy the report here.